Abstract:67 Background: Previous studies indicate a preexisting T cell response and the associated “adaptive immune resistance” are critical for the clinical efficacy of anti-PD-1/PD-L1 immunotherapy. The study explored the activated IFN-γ pathway and the expression of interferon regulatory factor 1 (IRF-1), as surrogates of preexisting T cell response, as potential biomarkers associated with clinical benefit (CB) for ESCC patients receiving anti-PD-1/PD-L1 therapy. Methods: Thirty-one ESCC patients treated with PD-1/PD-L1 blockade antibody, alone or in combination, were enrolled. Tumor response evaluation was made according to Response Evaluation Criteria in Solid Tumours 1.1, and CB was defined as complete response, partial response or stable disease at least 6 months. Formalin-fixed paraffin-embedded tissues from 31 patients were analyzed for the expression of PD-L1 and IRF-1 by immunohistochemistry; 13 tissues were analyzed for the expression of immune-related genes by NanoString nCounter Human PanCancer Immune Profiling. Results: Of 31 enrolled patients (M: F= 30: 1, median age of 58), 23 and 8 were of recurrent and de novo metastatic ESCC. Sixteen and 15 received PD-1/PD-L1 blockade alone and PD-1/PD-L1-based combination therapy, respectively; 13 had received at least 2 lines of systemic therapy for advanced disease. The response rate was 10%, and the CB rate was 16%. The median progression-free-survival (PFS) and overall survival are 1.8 and 5.6 months, respectively. The 25-gene IFN-γ signature was significant higher in patients with CB than in patients without CB ( P = 0.020). Neither PD-L1 expression on tumor cells (TC) nor on immune cells (IC) was associated with CB ( P = 0.489 and 0.646, respectively). However, the IRF-1 expression on TC or on IC was significantly associated with CB ( P < 0.001 and 0.005, respectively). Conclusions: Activated IFN-γ pathway determined by 25-gene IFN-γ signature and high IHC-expression of IRF-1 were associated with CB in advanced ESCC patients receiving anti-PD-1/PD-L1-based therapy. (Supported by the grant of MOST 105-2314-B-002 -186 -MY3).

Data from Negative Feedback Regulation of IFN-γ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers

Negative Feedback Regulation of IFN-γ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers

Negative Feedback Regulation Of Ifn-Gamma Pathway By Ifn Regulatory Factor 2 In Esophageal Cancers

Involvement of IFN Regulatory Factor (IRF)-1 and IRF-2 in the Formation and Progression of Human Esophageal Cancers

IRF1 Regulates the Progression of Colorectal Cancer Via Interferon‑induced Proteins.

Activated Interferon-Γ (Ifn-Γ) Pathway Associated with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1)/PD Ligand 1 (Pd-L1)-based Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

IRF-2 Inhibits Cancer Proliferation by Promoting AMER-1 Transcription in Human Gastric Cancer

IFN-γ Induces the Upregulation of RFXAP Via Inhibition of Mir-212-3p in Pancreatic Cancer Cells: A Novel Mechanism for IFN-γ Response.

Modulation of IFN-γ receptor 1 expression by AP-2α influences IFN-γ sensitivity of cancer cells.

Epigenetic Disruption of Interferon-Γ Response Through Silencing the Tumor Suppressor Interferon Regulatory Factor 8 in Nasopharyngeal, Esophageal and Multiple Other Carcinomas

Modulation Of Ifn-Gamma Receptor 1 Expression By Ap-2 Alpha Influences Ifn-Gamma Sensitivity Of Cancer Cells

Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion

Low-dose IFN-γ induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer

Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells

IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1

Clinical significance and biological function of interferon regulatory factor 1 in non-small cell lung cancer

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer

Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Tumor fibroblast-derived FGF2 regulates expression of SPRY1 in esophageal tumor-infiltrating T cells and plays a role in T cell exhaustion

Interferon Regulatory Factor (IRF)-1 and IRF-2 Are Associated with Prognosis and Tumor Invasion in HCC